Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals

• Type of Material: Article
• Authors: Jackson Mukonzo, Makerere University; Eleni Aklillu, Karolinska University Hospital; Vincent Marconi, Emory University; Raymond Schinazi, Emory University
• Language: English
• Date: 2019-06-01
• Publisher: ELSEVIER SCI LTD
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.ijid.2019.04.009
• Title of Journal or Parent Work: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
• Volume: 83
• Start Page: 98
• End Page: 101
• Grant/Funding Information: Supported in part by NIH CFAR grant P30-AI-050409 (to RFS and VM). We thank Drs. James Kohler and Selwyn Hurwitz for their critical comments.; Supported in part by an IAS –CIPHER grant kij-216 to JKM, supported in part by The Swedish Research Council (Vetenskapsrådet) grant 2015-03295 to JKM and EA.
• Keywords: MDR-TB; Drug-drug interactions; Life Sciences & Biomedicine; Treatment; Science & Technology; HIV; Infectious Diseases

Abstract

HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway–mediated drug–drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.